Fravær af signifikant farmakokinetisk interaktion med pravastatin er specifikt blevet demonstreret for adskillige lægemidler, særligt de som er substrater/ inhibitorer af CYP3A4, f. eks. diltiazem, verapamil, itraconazol, ketoconazol, proteaseinhibitorer, grapefrugt juice og CYP2C9 inhibitorer (f. eks. fluconazol).
The absence of a significant pharmacokinetic interaction with pravastatin has been specifically demonstrated for several products, particularly those that are substrates/inhibitors of CYP3A4 e.g. diltiazem, verapamil, itraconazole, ketoconazole, protease inhibitors, grapefruit juice and CYP2C9 inhibitors (e.g. fluconazole).